110 related articles for article (PubMed ID: 27457471)
1. Impact of Warfarin on Atrial-Fibrillation Outcomes Related to Economic Consumption Patterns: Hospitalization, Cost, and Mortality may be Predictable and Modifiable at the Population Level.
Kim MH; Cai Q; Xu L; Puckrein GA
Adv Ther; 2016 Sep; 33(9):1579-99. PubMed ID: 27457471
[TBL] [Abstract][Full Text] [Related]
2. Patient Diversity and Population Health-Related Cardiovascular Outcomes Associated with Warfarin Use in Atrial Fibrillation: An Analysis Using Administrative Claims Data.
Kim MH; Xu L; Puckrein G
Adv Ther; 2018 Nov; 35(11):2069-2080. PubMed ID: 30219991
[TBL] [Abstract][Full Text] [Related]
3. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
4. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
5. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation.
Mercaldi CJ; Ciarametaro M; Hahn B; Chalissery G; Reynolds MW; Sander SD; Samsa GP; Matchar DB
Stroke; 2011 Jan; 42(1):112-8. PubMed ID: 21148442
[TBL] [Abstract][Full Text] [Related]
6. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
[TBL] [Abstract][Full Text] [Related]
8. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
Masbah N; Macleod MJ
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
[TBL] [Abstract][Full Text] [Related]
9. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries.
Raji MA; Lowery M; Lin YL; Kuo YF; Baillargeon J; Goodwin JS
Ann Pharmacother; 2013 Jan; 47(1):35-42. PubMed ID: 23324508
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
11. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay.
Song X; Sander SD; Johnson BH; Varker H; Amin AN
Am J Health Syst Pharm; 2012 Feb; 69(4):329-38. PubMed ID: 22302258
[TBL] [Abstract][Full Text] [Related]
12. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
13. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.
Amin A; Keshishian A; Vo L; Zhang Q; Dina O; Patel C; Odell K; Trocio J
J Med Econ; 2018 Mar; 21(3):244-253. PubMed ID: 29047304
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
Ademi Z; Pasupathi K; Liew D
Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
[TBL] [Abstract][Full Text] [Related]
18. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
19. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.
Shen JI; Montez-Rath ME; Lenihan CR; Turakhia MP; Chang TI; Winkelmayer WC
Am J Kidney Dis; 2015 Oct; 66(4):677-88. PubMed ID: 26162653
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
